Antifungal Resistance Trends of Candida auris Clinical Isolates, New York-New Jersey, 2016-2020
15 January 2022
About 55% of U.S. Candida auris clinical cases were reported from New York and New Jersey from 2016 through 2020. Nearly all New York-New Jersey clinical isolates (99.8%) were fluconazole resistant, and 50% were amphotericin B resistant. Echinocandin resistance increased from 0% to 4% and pan-resistance increased from 0 to <1% for New York C. auris clinical isolates but not for New Jersey, highlighting the regional differences.
Further reading: Antimicrobial Agents and Chemotherapy
Author(s): Shannon Kilburn, MPH, Gabriel Innes, VDM, PhD, Monica Quinn, MS, Karen Southwick, MD, Belinda Ostrowsky, MD, Jane A. Greenko, MPH, Emily Lutterloh, MD, MPH, Rebecca Greeley, MPH, Reed Magleby, MD, MS, Vishnu Chaturvedi, PhD https://orcid.org/0000-0002-3922-9676, Sudha Chaturvedi, PhD
Effective Surveillance
OUR UNDERWRITERS
Unrestricted financial support by:
 |
LifeArc |
 |
Antimicrobial Resistance Fighter Coalition |
 |
Bangalore Bioinnovation Centre |
 |
INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS |
AMR NEWS
Every two weeks in your inbox
Because there should be one newsletter that brings together all One Health news related to antimicrobial resistance: AMR NEWS!